AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05009849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Exercises
Description: The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
Study NCT05009849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Exercises
Description: The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
Study NCT00839007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD-NP
Description: Infusion of CD-NP at one of up to 6 doses or placebo
Study NCT04015479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut Protein Powder
Description: Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
Study NCT04015479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full body resistance training
Description: Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
Study NCT04015479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full body resistance training
Description: Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
Study NCT02706600 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: myCOPD
Description: myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients.
Study NCT02706600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written Self management plan
Description: The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
Study NCT03361917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff Vision
Description: Subjects that are randomized to undergo their colonoscopy procedure with the Endocuff Vision device will have the device placed on the colonoscope that will be used during their procedure.
Study NCT04474288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibody testing
Description: venipuncture for SARS-CoV-2 IgG
Study NCT03091400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
Study NCT03091400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
Study NCT00243282 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation Response (instruction, pocket practice card prov)
Study NCT00243282 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness training using model developed from UMass
Study NCT02686710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study NCT02686710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT03932747 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pre- Hydratión skin
Description: Measurement of hydration of the skin.
Study NCT03932747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre- Hydratión skin
Description: Measurement of hydration of the skin.
Study NCT03932747 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: post- Hydratión skin
Description: Measurement of hydration of the skin.
Study NCT05902715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral implant placement with socket shield technique
Description: tooth is split in socket shield configuration, implant is immediately placed
Study NCT01173393 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: PARAMEDIC COOLING
Description: For patients randomised to paramedic cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~* If temperature >34.5ºC, infuse further 10mL/kg stat~* After ROSC, infuse further (max 2 litres) ice-cold saline~* If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg.
Study NCT02121847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine 0.05% ophthalmic emulsion
Description: Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
Study NCT02121847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose-based lubricant eye drops
Description: Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Study NCT02169908 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermotest
Study NCT02169908 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: von Frey hairs
Study NCT05794854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal aerobic endurance exercise
Description: Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks
Study NCT05794854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control training intervention
Description: Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
Study NCT03547661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P-Dragees rosa Lichtenstein
Description: Placebo dragées
Study NCT03729219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli ETVAX
Description: Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.
Study NCT03729219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study NCT04135053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilised Neisseria lactamica
Description: Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
Study NCT03585647 — intervention group
Intervention type: PROCEDURE
Intervention: hip arthroplasty
Description: Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
Study NCT03932747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post- Hydratión skin
Description: Measurement of hydration of the skin.
Study NCT04087759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (Reference formulation)
Description: Participants will receive bedaquiline orally.
Study NCT02377284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photograph
Description: Add a photograph to a chef card.
Study NCT01242332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 75 mg po 2 hrs before surgery
Study NCT03816956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-301
Description: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
Study NCT03816956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04209244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eskimo-3 Pure Fish Oil
Description: Dosage: 10 ml/day (2.6 g EPA+DHA)
Study NCT03397589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) services
Description: CHWs are non-clinical people who provide education, care coordination, and support to families.
Study NCT02361099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring by SENTINEL application
Description: Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
Study NCT04209244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rapeseed Oil
Description: Dosage: 10 ml/day (0 g EPA+DHA)
Study NCT01731574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Study NCT01731574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapivirine
Study NCT01731574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: miconazole
Study NCT01179139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith \& Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
Study NCT01179139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith \& Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
Study NCT03478774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen 70l/min
Description: HFNCT will be provided using OptiFlow by Fisher\&Paykel.
Study NCT03478774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 70l/min
Description: HFNCT will be provided using OptiFlow by Fisher\&Paykel.
Study NCT03478774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 10 l/min
Description: Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
Study NCT03478774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 2l/min
Description: Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
Study NCT03478774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jaw thrust
Description: Continuous
Study NCT03478774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscopy
Description: Continuous
Study NCT03478774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen 0.25l/min
Description: 0.25l/min of oxygen via an endotracheal tube
Study NCT02017535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
Study NCT02017535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
Study NCT02017535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
Study NCT02017535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
Study NCT01336309 — intervention group
Intervention type: BEHAVIORAL
Intervention: Yoga Research Tool
Description: We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
Study NCT02067585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Lipid meals
Description: Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
Study NCT05155072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: DW1903
Study NCT03695783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online decision aid called IBD&me
Description: Patients randomized to IBD\&me will be directed to go through the website at least 2 days before their clinic appointment, and will be asked to bring their personalized report with them to their upcoming visit.
Study NCT03695783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized educational material
Description: Patients randomized to the control arm will be sent a PDF file corresponding to the CCFA's online resource at least 2 days before their clinic appointment, and will be asked to bring it with them to their upcoming visit.
Study NCT05155072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R1
Description: DW1903-R1
Study NCT05155072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903-R2
Description: DW1903-R2
Study NCT03985618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
Study NCT03985618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction of Labour
Description: Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
Study NCT03359980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transfer
Description: transfer of fecal microbiota from healthy donors to the patients
Study NCT01672632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding
Description: We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
Study NCT00506961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
Study NCT00506961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
Study NCT02311179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis, BoneMaster-Exceed cup (Biomet)
Description: Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
Study NCT02311179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis Exceed cup without HA (Biomet)
Description: Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
Study NCT02293187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level \<70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
Study NCT02293187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
Study NCT01410448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
Study NCT01410448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
Study NCT01410448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Description: Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
Study NCT01410448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
Study NCT01410448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
Study NCT01410448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Steroids were administered according to local clinical practice.
Study NCT01410448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Steroids were administered according to local clinical practice.
Study NCT01185574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Vitamin D2 50,000 IU will be administered once a week for six months.
Study NCT02535065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith Low Profile AAA Endovascular Graft and ancillary components
Description: Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
Study NCT03708939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Daily consumption of 5g of glucose, for 14 days.
Study NCT03708939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspartame
Description: Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.
Study NCT03708939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.
Study NCT03708939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharin
Description: Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.
Study NCT03708939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stevia
Description: Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.
Study NCT03708939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Supplement
Description: Follow up without any dietary supplementation.
Study NCT02045758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fingerstick
Study NCT02045758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP20-C